FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.

Nicole Verdun at 2023 ASGCT Policy Summit
Nicole Verdun (left) discussed accelerated approval and other cell and gene therapy issues during the ASGCT Policy Summit. • Source: Screenshot of conference livestream

More from Cell & Gene Therapies

More from Advanced Technologies